Verquvo (vericiguat) / Bayer, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   27 Trials   27 Trials   1089 News 


«12345678910111213...1516»
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    A Systematic Review And Network Meta-analysis In HfpEF Pharmacologic Treatment (Zone 2, Science and Technology Hall, Level 3; Poster Board no. 2156) -  Aug 20, 2022 - Abstract #AHA2022AHA_6326;    
    We included patients with heart failure and left ventricular ejection fraction >40%, treated with any of the following therapies: angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), beta-blockers (BB), MRA, digoxin, ARNi, SGLT2i, and vericiguat. In patients with HFpEF, MRA and SGLT2i alone as well as a combination of ACE-i/ARB, BB, MRA and SGLT2i were associated with decreased risk of CV mortality and HHF.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Review, Journal:  Update on diagnostics and treatment of heart failure (Pubmed Central) -  Aug 11, 2022   
    Thus, the treatment of patients with heart failure represents a substantial challenge for the German healthcare system. This article highlights the latest scientific knowledge on acute and chronic heart failure from the years 2018-2020.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
    Retrospective data, Journal:  Network meta-analysis of medical therapy efficacy in more than 90000 patients with heart failure and reduced ejection fraction. (Pubmed Central) -  Jul 24, 2022   
    Patients with highest NT-proBNP values are probably too far advanced, suffering more co-morbidities, or still clinically unstable after decompensation to derive benefit from vericiguat. Combination medical therapy including neurohormonal inhibitors and newer drugs, especially ARNI and SGLT2i, confers the maximum benefit with regard to HFrEF prognosis.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Review, Journal:  Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction. (Pubmed Central) -  Jul 15, 2022   
    AEs of special interest included symptomatic hypotension and syncope, which occurred with low incidences that were similar between treatment groups. Thus, vericiguat is an effective and generally well-tolerated treatment option in patients with symptomatic, chronic HFrEF who have experienced a recent worsening event, expanding the options currently available for chronic HFrEF management.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    What if... you have decided to prescribe vericiguat for your patient? (The Hub - Miro) -  Jun 27, 2022 - Abstract #ESC2022ESC_5416;    
    The regulatory effects of Vericiguat on OCs were achieved by the bidirectional modulation of the IκB-α/NF-κB signaling pathway, and a potential balance between the IκB-α/NF-κB signaling pathway and sGC/cGMP/VASP may exist. sponsored by Bayer AG
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Time to act: what if your patient is in need of a different strategy following a worsening heart failure event? (The Hub - Miro) -  Jun 27, 2022 - Abstract #ESC2022ESC_5414;    
    sponsored by Bayer AG sponsored by Bayer AG Discuss clinical decision-making for the treatment of patients with HFrEF following a worsening HF event Review the clinical benefits of vericiguat in this patient population and its role in the current treatment landscape Consider the practical implementation of vericiguat in patients with HFrEF following a worsening HF event
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Review, Journal:  Current and emerging drug targets in heart failure treatment. (Pubmed Central) -  Jun 22, 2022   
    More recently, sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, combining inhibition of RAAS and potentiation of the counter-regulatory natriuretic peptide system, has been consistently demonstrated to reduce mortality and HF-related hospitalization...Among them, drugs acting directly at a second messenger level, such as the soluble guanylate cyclase stimulator vericiguat, or other addressing myocardial energetics and mitochondrial function, such as elamipretide or omecamtiv-mecarbil, will likely change the therapeutic management of patients with HF...Most of these emerging approaches have shifted the therapeutic target from neurohormonal systems to the heart, by improving cardiac contractility, metabolism, fibrosis, inflammation, and remodeling. In the present paper, we review from a pathophysiological perspective current and novel therapeutic strategies in chronic HF.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Review, Journal:  The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. (Pubmed Central) -  Jun 22, 2022   
    The phase 3 VICTORIA trial found that vericiguat is safe and effective in patients with HFrEF and recent HF decompensation. Therefore, adding vericiguat may be considered in individual patients with HFrEF, particularly those at higher risk of HF hospitalization; the efficacy of the sacubitril/valsartan-vericiguat combination in HFrEF is currently unknown.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Real-world eligibility for vericiguat according to trial, guideline, and labelling eligibility criteria: data from the Swedish Heart Failure Registry (Research Gateway 3) -  Jun 15, 2022 - Abstract #ESC2022ESC_3675;    
    In a large and contemporary real-world cohort of HF with EF<40%, eligibility for vericiguat according to the trial and guideline scenarios was limited, i.e. ~20-25%, whereas it was higher according to the labelling scenario, i.e. ~45%. The VICTORIA trial's selection criteria successfully selected a HF population enriched for CV events but also with a higher risk of non-CV events, which is consistent with more severe HF and comorbidities in eligible vs. ineligible patients, but the requirement for recent worsening HF also rendered many patients ineligible.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Review, Journal:  Vericiguat in heart failure: From scientific evidence to clinical practice. (Pubmed Central) -  Jun 9, 2022   
    Vericiguat is able to stimulate the activity of this protective pathway. The VICTORIA study demonstrated that the addition of vericiguat to optimal medical treatment in patients with HFrEF and recent decompensation significantly reduced the incidence of the primary endpoint, a composite of cardiovascular death or HF hospitalization, with a number needed to treat of 24 patients and excellent tolerability.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Vericiguat: A Novel Soluble Guanylate Cyclase Stimulator For Use in Patients with Heart Failure. (Pubmed Central) -  May 25, 2022   
    The aim of this review is to provide a comprehensive literature analysis of the various trials surrounding the approval of Vericiguat, and to both inform and synthesize the data surrounding the clinical use of Vericiguat. The introduction of Vericiguat should be considered as a treatment option in patients to decrease the mortality/morbidity of heart failure with reduced ejection fraction, and to increase the quality of life.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Clinical, Journal, Combination therapy:  Vericiguat in Combination with Short-Acting Nitroglycerin in Patients with Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study. (Pubmed Central) -  May 22, 2022   
    Decreases in mean blood pressure (BP; 6-10 mmHg systolic BP [SBP]; 4-6 mmHg diastolic BP [DBP]) were independent of vericiguat exposure and occurred to a similar extent at trough and peak concentrations with all vericiguat doses and placebo. Co-administration of vericiguat with nitroglycerin in patients with CCS was well tolerated, and the combination is unlikely to cause significant adverse effects beyond those known for nitroglycerin.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Journal:  Renal effects of guideline directed medical therapies in heart failure - a consensus document from the Heart Failure Association of the European Society of Cardiology. (Pubmed Central) -  May 18, 2022   
    The emerge of several new classes (angiotensin receptor-neprilysin inhibitor [ARNI], SGLT2 inhibitors, vericiguat, omecamtiv mecarbil) and the recommendation by the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic HF of early initiation and titration of quadruple disease-modifying therapies (ARNI/angiotensin-converting enzyme inhibitor + beta-blocker + mineralocorticoid receptor antagonist and SGLT2 inhibitor) in HFrEF increases the likelihood of treatment-induced changes in renal function. No abstract available